A photo of John Perentesis.

Director, Division of Oncology

Institute Co-Director, Cancer and Blood Diseases Institute

Deb Kleisinger Endowed Chair

Professor, UC Department of Pediatrics



Best Doctors logo

My Biography & Research


John P. Perentesis, MD, FAAP, is a nationally recognized expert in the development of new drugs and molecular therapies for pediatric and young adult cancers and leukemia. His laboratory has developed novel anticancer drugs and discovered genes important in the growth of normal and malignant cells. His laboratory is also using tumor patients genomics research for personalizing therapies. In national efforts for new anticancer drug development, he serves in key roles for the National Cancer Institute’s Investigational Drug Steering Committee and the NCI-funded Children’s Oncology Group (COG). The COG is the world's largest children's cancer research entity.

In 2010, Dr. Perentesis was elected by pediatric oncologists from across the country to the national COG Executive Committee. He also serves as vice-chair for the COG Adolescent & Young Adult Cancer Steering Committee and as a member of the Hematology/Oncology and Institutional Performance Monitoring Steering Committees.

Dr. Perentesis has been elected by his peers for inclusion in the Best Doctors in America List since 1998.

Clinical Interests

Young adult cancers; acute myeloid & lymphoid leukemia; Hodgkin lymphoma; new anticancer therapy development

Research Interests

Molecular etiology and pharmacogenetics of pediatric cancers; Down syndrome-associated leukemia; new anticancer drug development

Academic Affiliation

Professor, UC Department of Pediatrics


Leukemia, Sarcoma, Oncology, Cancer and Blood Diseases, Cancer and Blood Diseases, Best Doctors, Young Adult Cancer

My Locations

My Education

MD: University of Michigan, Ann Arbor, MI, 1980.

Residency: University of Minnesota Medical School, Minneapolis, MN, 1983.

Fellowship: University of Minnesota Medical School, Minneapolis, MN, 1986.

Postdoctoral: University of Minnesota Medical School, Minneapolis, MN, 1986.

Certification: Pediatrics, 1989; Hematology/Oncology, 1990.

My Publications

Dorris K, Fouladi M, Davies SM, Perentesis JP, Lawrence JM, Chow LM, Assa'ad A, Uygungil B, Jodele S. . Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. J Pediatr Hematol Oncol. 2011 Jun 3.

Davies SM, Perentesis JP. Tribute: the American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatr Blood Cancer. 2011 Jun;56(6):895-6.

Phillips CL, Gerbing R, Alonzo T, Perentesis JP, Harley IT, Meshinchi S, Bhatla D, Radloff G, Davies SM. MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2010 Aug;55(2):248-53.

Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD Jr, Ingle AM, Blaney SM, Adamson PC. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study. Pediatr Blood Cancer. 2010 Apr;54(4):538-45.

Mehta PA, Gerbing RB, Alonzo TA, Elliott JS, Zamzow TA, Combs M, Stover E, Ross JA, Perentesis JP, Meschinchi S, Lange BJ, Davies SM. FAS promoter polymorphism: outcome of childhood acute myeloid leukemia. A children's oncology group report. Clin Cancer Res. 2008 Dec 1;14(23):7896-9.

Bhatla D, Gerbing RB, Alonzo TA, Conner H, Ross JA, Meshinchi S, Zhai X, Zamzow T, Mehta PA, Geiger H, Perentesis J, Davies SM. Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol. 2009 Feb;144(3):388-94.

Geller JI, Wall D, Perentesis J, Blaney SM, Bernstein M; Pediatric Oncology Group study 9376. Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: a Pediatric Oncology Group study (POG 9376). Pediatr Blood Cancer. 2009 Mar;52(3):346-50.

Johansson G, Mahller YY, Collins MH, Kim MO, Nobukuni T, Perentesis J, Cripe TP, Lane HA, Kozma SC, Thomas G, Ratner N. Effective in vivo targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2008 May;7(5):1237-45.

Bhatla D, Gerbing RB, Alonzo TA, Mehta PA, Deal K, Elliott J, Meshinchi S, Geiger H, Perentesis JP, Lange BJ, Davies SM; Children's Oncology Group. DNA repair polymorphisms and outcome of chemotherapy for acute myelogenous leukemia: a report from the Children's Oncology Group. Leukemia. 2008 Feb;22(2):265-72.

Mo J, Lampkin B, Perentesis J, Poole L, Bao L. Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. Cancer Genet Cytogenet. 2006 Feb;165(1):75-8. Review.